Symposium of the XXth Collegicum Internationale Neuro Psychopharmacologicum (CINP) Congress, Melbourne, Australia, 25 June 1996: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization

Molecular Psychiatry

Volumn 4, Issue 6, 1999, Pages 512-523

  Yui, K ^a   Goto, K ^b   Ikemoto, S ^a   Ishiguro, T ^a   Angrist, B ^c   Duncan, G E ^d   Sheitman, B B ^d   Lieberman, J A ^d   Bracha, S H ^e   Ali, S F ^f  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Pacific Center for PTSD   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cocaine psychosis; Dopamine; Methamphetamine psychosis; Noradrenaline; Phencyclidine; Rotational behavior; Schizophrenia; Sensitization; Spontaneous recurrence; Stimulant; Stress

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; COCAINE; METHAMPHETAMINE; PHENCYCLIDINE; ADRENERGIC RECEPTOR STIMULATING AGENT; PSYCHEDELIC AGENT;

CONFERENCE PAPER; DRUG SENSITIZATION; HUMAN; NEUROBIOLOGY; NEUROCHEMISTRY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; STRESS; SUBSTANCE ABUSE; ANIMAL; BRAIN LEVEL; COCAINE DEPENDENCE; DRUG EFFECT; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PREDICTION AND FORECASTING; RECURRENT DISEASE; REVIEW;

ANIMALS; BRAIN CHEMISTRY; COCAINE-RELATED DISORDERS; HALLUCINOGENS; HUMANS; METHAMPHETAMINE; PHENCYCLIDINE; PREDICTIVE VALUE OF TESTS; PSYCHOSES, SUBSTANCE-INDUCED; RECURRENCE; SCHIZOPHRENIA; SENSORY THRESHOLDS; SYMPATHOMIMETICS;

EID: 0033220033     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000575     Document Type: Conference Paper

References (112)

1. 1 Angrist B, Poselow E, Rubinstein M, Wolkin A, Rotrosen J. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 1985; 85: 277-283.
2. 2 Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994; 11: 107-118.
3. 3 Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 1979; 5: 73-77.
4. 4 Utena H. Behavioral alterations in methamphetamine-intoxicated animals and chemical correlates in the brain. Prog Brain Res 1966; 21B: 192-207.
5. 5 Barlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability. Neuropsychopharmacology 1997; 16: 77-82.
6. 6 Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965; 111: 701-707.
7. 7 Yui K, Goto K, Ikemoto S, Ishiguro T. Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. J Clin Psychopharmacol 1997; 17: 34-43.
8. 8 Yui K, Ishiguro T, Goto K, Ikemoto S. Precipitating factors in spontaneous recurrence of methamphetamine psychosis. Psychopharmacology 1997; 134: 303-308.
9. 9 Robinson TE, Becker JB, Young EA, Akil H, Castaneda K. The effects of footshock stress on regional brain dopamine metabolism and pituitary β-endorphin release in rats previously sensitized to amphetamine. Neuropharmacology 1987; 20: 679-691.
10. 10 Irwin J, Ahiluwalia P, Anisman H. Sensitization of norepinephrine activity following acute and chronic footshock. Brain Res 1986; 379: 98-103.
11. 11 Nisenbaum LK, Zigmond MJ, Sved AF, Abercrombie ED. Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor. J Neurosci 1991; 11: 1478-1484.
12. 12 American Psychiatric Association. Diagnostic and Statistical Disorders, 4th edn. APA: Washington, DC, 1994.
13. 13 Matefy RE, Hayes C, Hirsh J. Psychedelic drug flashbacks: subjective reports and biographical data. Addict Behav 1978; 3: 165-178.
14. 14 American Psychiatric Association. Diagnostic and Statistical Disorders. 3rd edn, revised. APA: Washington, DC, 1987.
15. 15 Antelman SM, Eichler AJ, Black CA, Kocan D. Interchangeability of stress and amphetamine in sensitization. Science 1980; 207: 329-331.
16. 16 Wood PL, Altar A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 1988; 40: 163-187.
17. 17 Kent AP, Stern GM, Webster RA. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat. Br J Pharmacol 1990; 100: 743-748.
18. 18 Charpusta SJ, Wyatt RJ, Masserano JM. Effects of single and repeated footshock nn dopamine release and metabolism in the brains of Fisher rats. J Neurochem 1997; 68: 2024-2031.
19. 19 Bremner JD, Krystal JH, Southwick SM, Charney DS. Functional neuroanatomical correlates of the effects of stress on memory. J Traumatic Stress 1995; 8: 527-553.
20. 20 Southwick SM, Krystal JH, Morgan CA. Johnson D, Nagy LM, Nicolaou A et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50: 266-274.
21. 21 Roy A, Pickar D, Jong JD, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Arch Gen Psychiatry 1988; 45: 849-857.
22. 22 Green AL, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME et al. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 1993; 10: 33-37.
23. 23 Risbo A, Jessen K, Hageisten JO. Catecholamine response to the clinical use of alpha adrenergic receptor blocking agents. Acta Anaesthesiol Scand 1983; 27: 72-74.
24. 24 Tuck JR. Effects of chlorpromazine, thioridazine and haloperidol on adrenergic transmitter mechanisms in man. Eur J Clin Pharmacol 1973; 6: 81-87.
25. 25 Westerink BHC, Spaan SJ. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 1962; 38: 680-666.
26. 26 Davidoff E, Reifenstein EC. Treatment of schizophrenia with sympathomimetic drugs: benzedrine sulfate. Am J Psychiatry 1939; 95: 127-143.
27. 27 Schube PG, McManarny MC, Trapp CE. The effect of benzedrine sulfate on certain abnormal mental states. Am J Psychiatry 1937; 94: 27-32.
28. 28 Lieberman JA, Kane JM, Alvir J. Provocative tests with psychosimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-433.
29. 29 Janowsky DS, El Yousef K, Davis JM, Sekerke J. Provocation of schizophrenic symptoms by intravenous methylphenidate. Arch Gen Psychiatry 1973; 28: 185-191.
30. 30 van Kammen DP, Docherty JP, Bunney WE Jr. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 1982; 17: 233-242.
31. 31 Lieberman JA, Kane J, Sarantakos S, Gadaleta D, Woerner M, Alvir J et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987; 44: 597-603.
32. 32 Davidson M, Keefe RS, Mohs RC, Siever LJ, Losoncy MF, Horvath T et al. L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 1987; 144: 934-938.
33. 33 Angrist B, Peselow E, Rotrosen J, Gershon S. Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. In: Angrist B, Burrows G, Lader M (eds). Advances in the Biosciences, vol 31: Recent Advances in neuropsychopharmacology. Pergamon Press: Oxford, New York, 1981, pp 49-54.
34. 34 Post RM, Weiss SRB, Pert A, Uhde TW. Chronic cocaine administration: sensitization and kindling effects. In: Fisher S, Raskin A, Uhlenhuth EH (eds). Cocaine: Clinical and Biobehavioral Aspects. Oxford University Press: New York, 1987, pp 109-173.
35. 35 Satel SL, Southwick SM, Gawin FH. Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991; 148: 495-498.
36. 36 Brady KT, Lydiard B, Malcolm R, Ballinger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-512.
37. 37 Schulz SC, Cornelius J, Schulz PM, Soloff PH. The amphetamine challenge test in patients with borderline disorder. Am J Psychiatry 1988; 145: 809-814.
38. 38 Satel S, Edell WS. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991; 148: 1708-1711.
39. 39 Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-291.
40. 40 Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiat Res 1974; 11: 13-23.
41. 41 Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-351.
42. 42 McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19: 71-84.
43. 43 Carpenter WT Jr, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 1988; 14: 645-652.
44. 44 Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188.
45. 45 Huber G, Gross C, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980; 6: 592-605.
46. 46 Crow TJ, MacMillan JR, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 248: 120-127.
47. 47 Lieberman JA, Korcen A, Chakos M, Sheitman B, Woener M, Alivir J et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57: 5-9.
48. 48 Griffith J, Cavanaugh J, Held N, Oates J. D-amphetamine: evaluation of psychotomimetic properties in man. Arch Gen Psychiatry 1972; 26: 97-100.
49. 49 Tatesu S, Goto A, Fujiwara T. The Methamphetamine Psychosis. Igakushoin: Tokyo, 1956 (in Japanese).
50. 50 Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992; 18: 115-122.
51. 51 Robinson TE, Henker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986; 11: 157-198.
52. 52 Akiyama K, Kanzaki A, Tsuchida K, Ujike H. Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophr Res 1994; 12: 251-257.
53. 53 Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990; 16: 97-109.
54. 54 Ellison GD, Eison M, Huberman H, Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 1978; 201: 276-278.
55. 55 Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic patients. Psychopharmacology 1980; 67: 31-38.
56. 11C] raclop-ride in the human brain. Synapse 1994; 16: 255-262.
57. 57 Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci 1997; 94: 2569-2574.
58. 58 Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240.
59. 59 Norman RM, Malla AK. Stressful life events and schizophrenia. 1: A review of the research. Br J Psychiatry 1993; 162: 161-166.
60. 60 Leff J. Stress reduction in the social environment of schizophrenic patients. Acta Psychiatr Scand 1994; 90 (suppl 384): 133-139.
61. 61 Kane JM, Lieberman JA. Maintenance pharmachotherapy in schizophrenia. In: Meltzer HY (ed). Psychopharmacology: the 3rd Generation of Progress, Raven Press: New York, 1987, pp 1103-1109.
62. 62 Horger BA, Roth RH. The role of mesafrontal dopamine neurons in stress. Crit Rev Neurobiol 1996; 10: 395-418.
63. 63 Moghaddam B, Stress preferentially activates extraneuronal levels of excitatory amino acids in the prefrontal cortex: a comparison to hippocampus and basal ganglia. J Neurochem 1993; 60: 1650-1657.
64. 64 Ducan GE, Knapp DJ, Johnson KB, Breese GR. Functional classification of antidepressants based upon antagonism of swim stress-induced Fos-like immunoreactivity. J Pharmacol Exp Ther 1996; 277: 1076-1089.
65. 65 Hamamura T, Fibiger HC. Enhanced stress-induced dopamine release in the prefrontal cortex of amphetamine-sensitized rats. Eur J Pharmacol 1993; 237: 85-72.
66. 66 Hasselmo ME. Neuromodulation and cortical function: modeling the physiological basis of behavior. Behav Brain Res 1995; 67: 1-27.
67. 67 Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiat Res 1982; 17: 4319-4334.
68. 68 Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 1993; 91: 111-134.
69. 69 Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984; 4: 2877-2890.
70. 70 von Voightlander PF, Moore KE. Involvement of nigrostriatal neurons in the in-vivo release of dopamine by amphetamine, amantadine, and tyramine. J Pharmacol Exp Ther 1971; 164: 542-552.
71. 71 White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221: 1054-1057.
72. 72 Roth RH, Tam SY, Ida Y, Yang JX, Deutch AY. Stress and the mesocorticolimbic dopamine system. Ann NY Acad Sci 1988; 537: 138-147.
73. 73 Pycock CJ, Carter CJ, Kerwin RW. Effects of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 1980; 34: 91-99.
74. 74 Yoshikawa T, Shibuya H, Kaneno S, Toru M. Blockade of behavioral sensitization to methamphetamine by lesion of hippocampal-accumbal pathway. Life Sci 1991; 48: 1325-1332.
75. 75 Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
76. 76 Jaskiw GE, Karoum F, Weinberger DR. Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res 1990; 534: 321-323.
77. 77 Lipska BK, Weinberger DR. Cortical regulation of the mesolimbic dopamine system: implications for schizophrenia. In: Kalivas PW, Barnes CD (eds). Limbic Motor Circuits and Neuropsychiatry. CRC Press: Boca Raton, 1993, pp 329-349.
78. 78 Fauman, BJ, Fauman MA. Phencyclidine abuse and crime: a psychiatric perspective. Bull AAPL 1982; 10: 171-176.
79. 79 Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
80. 80 Ludy ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model psychosis and schizophrenia. Am J Psychiatry 1962; 119; 61-67.
81. 81 Erand R, Luisada PV, Peele R. The PCP psychosis: prolonged intoxication on drug-precipitated functional illness? J Psychedelic Drugs 1980; 12: 235-245.
82. 82 Showalter CV, Thornton WE. Clinical pharmacology of phencyclidine toxicity. Am J Psychiatry 1977; 134: 1234-1241.
83. 83 Yesavage JA, Freeman AM, Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J Clin Psychiatry 1978; 44; 664-665.
84. 84 Sturgeon RD, Fessler RG, London SF, Meltzer HY. Behavioral effects of chronic phenycyclidine administration in rats. Psychopharmacology 1982; 76: 52-56.
85. 85 Sturgeon RD, Fessler RG, Meltzer HY. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979; 59: 169-179.
86. 86 Smith RC, Biggs CA, Leelavathi DE, Altshuler HL. Behavioral effects of acute and chronic phencyclidine in the rat. Neurosci Abstr 1978; 4: 503.
87. 87 Kanner M, Finnega K, Meltzer HY. Dopaminergic effects of phenyclidine in rats with nigrostriatal lesions. Psychopharmac Communs 1975; 114: 393-401.
88. 88 Glick SD, Meibach RC, Cox RD, Maayanii S. Phenycyclidine-induced rotation and hippocampal modulation of nigrostriatal asymmetry. Brain Res 1980; 196: 99-107.
89. 89 Greenberg BD, Segal DS. Acute and chronic behavioral interaction between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCO-induced behaviors. Pharmacol Biochem Behav 1985; 23: 99-105.
90. 90 Yamaguchi K, Nabeshima T, Kameyama T. Role of dopaminergic and serotonergic neuronal system in the profrontal cortex of rats in phencyclidine-induced behaviors. J Pharmacobio-Dyn 1986; 9: 987-996.
91. 91 Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Furukawa H, Kameyama T. Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol Biochem Behav 1984; 21: 401-108.
92. 92 Sircar R, Rappaport M, Nichterhauser R, Zukin SR. The novel anticonvulsant MK-801: a potent and specific ligand of the brain phencyclidine/or receptor. Brain Res 1987; 435: 235-242.
93. 93 Fessler RG, Sturgeon RD, Meltzer HY. Phencyclidine-induced ipsilateral rotation in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra. Life Sci 1979; 24: 1281-1288.
94. 94 Glick SD, Cox RD. Nocturnal rotation in normal rats: correlation with amphetamine-induced rotation and effects of nigrostriatal lesions. Brain Res 1978; 150: 149-161.
95. 95 Glick SD, Hinds PA, Shapiro RM. Cocaine-induced rotation, sex-dependent differences between left and right sided rats. Science 1983; 221: 775-777.
96. 96 Christie J, Crow TJ. Turning behavior as an index of the action of amphetamines and ephedrine on central dopamine-containing neurons. Br J Pharmacol 1971; 43: 658-667.
97. 97 Hiramatsu M, Cho AK, Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonist, MK-801 and phencyclidine. Eur J Pharmacol 1989; 166: 359-366.
98. 98 Iverson SD, Singh L, Oles RJ, Preston G, Tricklebank MD. Psychopharmacological profile of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801, In: Domino EF, Kamenka JM (eds). Sigma and Phencyclidine-like Compounds as Molecular Probe in Biology. NPP Books: Ann Arbor, 1988, p 373.
99. 99 Koek W, Woods JH, Winger GD, MK-810, a proposed non-competitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkey. J Pharmacol Exp Ther 1988; 245: 969-978.
100. 100 Koek W, Woods JH. Correlation between phencyclidine-like activity and N-methyl-D-aspartate antagonist: behavioral evidence. In: Domino EF, Kamenka JM (eds). Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology. NPP Books: Ann Arbor, 1988; pp 357-368.
101. 101 Olney JW, Labruyar J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244: 1360-1362.
102. 102 Bracha HS. Asymmetric rotational (circling) behavior. A dopamine-related asymmetry: preliminary finding in unmedicated and nerve-medicated schizophrenic patients. Biol Psychiatry 1987; 22: 995-1003.
103. 103 Bracha HS, Livingston RL, Clotheir J, Linington BB, Karson CN. Correlation of severity of psychiatric patient's delusions with right hemispatial inattention (left turning behavior). Am J Psychiat 1993; 150: 330-332.
104. 104 Ungerstedt V, Arbuthnot GW. Quantitative recording of behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493.
105. 105 Glick SD, Ross DA. Lateralisation of function in the rat brain mechanisms may be operative in humans. Trends Neurosci 1981; 4: 198-199.
106. 106 Ali SF, Newport GD, Bracha HR. Phencyclidine, (+)-MK-801-induced circling preference in rats: correlation with monoamine levels in striatum of the rat brain. Neurotox Teratol 1993; 16: 335-342.
107. 107 Domino EF, Luby ED. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino EF (ed). PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor: NPP Books, 1981, pp 401-418.
108. 108 Scalzo FM, Holson RR. The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicol Terato 1992; 14: 7-14.
109. 109 Ali SF, Kordsmeier KJ, Gough B. Drug-induced circling preference in rats: correlation with monoamine levels. Mol Neurobiol 1995; 11: 145-154.
110. 110 Gur RE, Skolnick BE, Caroff S, Obrist WD, Resnick S, Reivich M. Brain function in psychiatric disorders: II. Regional cerebral blood flow in unmedicated schizophrenics. Arch Gen Psychiat 1985; 42: 329-334.
111. 111 Early TS, Reiman EM, Raichle ME, Spitzinagel EL. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA 1987; 84: 561-565.
112. 112 Early TS, Posner MI, Reiman EM, Raichle ME. Hyperactivity of the striato-pallidal projection, Part I: lower level of theory. Psychiat Dev 1989; 2: 85-108.